Does LEUPROLIDE Cause Bladder transitional cell carcinoma? 17 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 17 reports of Bladder transitional cell carcinoma have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.0% of all adverse event reports for LEUPROLIDE.
17
Reports of Bladder transitional cell carcinoma with LEUPROLIDE
0.0%
of all LEUPROLIDE reports
1
Deaths
4
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From LEUPROLIDE?
Of the 17 reports, 1 (5.9%) resulted in death, 4 (23.5%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
Yes, Bladder transitional cell carcinoma is listed as a known adverse reaction in the official FDA drug label for LEUPROLIDE.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which LEUPROLIDE Alternatives Have Lower Bladder transitional cell carcinoma Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM